Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol

被引:9
作者
Henderson, Linda S.
Tenero, David M.
Campanile, Andrea M.
Baidoo, Charlotte A.
Danoff, Theodore M.
机构
[1] GlaxoSmithKline Inc, Dept Clin Pharmacol & Discovery Med, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline Inc, Dept Clin Pharmacokinet Modeling & Simulat, King Of Prussia, PA 19406 USA
[3] GlaxoSmithKline Inc, Dept Clin Sci & Study Operat, King Of Prussia, PA 19406 USA
[4] GlaxoSmithKline Inc, Dept Clin Pharmacol Stat & Programming, King Of Prussia, PA 19406 USA
关键词
carvedilol; controlled-release; ethanol; pharmacokinetics;
D O I
10.1177/0091270007307244
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The concomitant ingestion of alcohol may alter the release of a drug from a modified-release dosage form, posing a potential risk to patients. In a randomized, open-label, 4-period cross-over study, the pharmacokinetic profiles of R(+) and S(-) carvedilol were compared after a single oral dose of carvedilol controlled-release formulation (administered following a standard meal) was given alone or concomitantly with ethanol. Thirty-nine healthy subjects participated in this study. Following coadministration of carvedilol controlled-release 40 mg with ethanol (approximately 38 g), ethanol ingestion 2 hours before or 2 hours after carvedilol controlled-release administration, area under the curve for the R(+) and S(-) carvedilol enantiomers was similar compared with carvedilol controlled-release given alone. Carvedilol exposure was not affected by the concomitant administration of ethanol and carvedilol controlled-release. Maximum plasma concentrations for the R(+) and S(-) carvedilol enantiomers were similar except when ethanol was ingested 2 hours after carvedilol controlled-release administration, where there was a modest decrease in maximum plasma concentration for R(+) and S(-) carvedilol (16% and 17%, respectively). Carvedilol controlled-release given alone or concomitantly with ethanol ingestion was generally well tolerated, and no serious or severe adverse events were reported. Ethanol did not alter the pharmacokinetic profile of carvedilol controlled-release.
引用
收藏
页码:1358 / 1365
页数:8
相关论文
共 15 条
[1]  
BOYLE DU, 1990, CLIN PHARMACOL THER, V49, P126
[2]   GASTRIC-EMPTYING AND GASTROINTESTINAL ABSORPTION OF ALCOHOL INGESTED WITH A MEAL [J].
CORTOT, A ;
JOBIN, G ;
DUCROT, F ;
AYMES, C ;
GIRAUDEAUX, V ;
MODIGLIANI, R .
DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (04) :343-348
[3]  
DAVENPORT HW, 1982, GASTRIC SECRETION DI
[4]   DOSE-EFFECT AND PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS OF THE BETA(1)-ADRENERGIC RECEPTOR BLOCKING PROPERTIES OF VARIOUS DOSES OF CARVEDILOL IN HEALTHY HUMANS [J].
DEMEY, C ;
BREITHAUPT, K ;
SCHLOOS, J ;
NEUGEBAUER, G ;
PALM, D ;
BELZ, GG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) :329-337
[5]   Carvedilol - A review of its use in chronic heart failure [J].
Keating, GM ;
Jarvis, B .
DRUGS, 2003, 63 (16) :1697-1741
[6]   Use of measurements of ethanol absorption from stomach and intestine to assess human ethanol metabolism [J].
Levitt, MD ;
Li, R ;
DeMaster, EG ;
Elson, M ;
Furne, J ;
Levitt, DG .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1997, 273 (04) :G951-G957
[7]  
MEYER RJ, 2005, M FOOD DRUG ADM ADV
[8]   Results of therapy with carvedilol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients [J].
Moser, M ;
Frishman, W .
AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (01) :15S-22S
[9]  
*NAT I ALC AB ALC, HELP PAT WHO DRINK C
[10]  
Rosito GA, 1999, AM J HYPERTENS, V12, P236